BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOLFree Report) in a report released on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Several other equities research analysts have also recently weighed in on BIOL. Ascendiant Capital Markets lowered their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Benchmark reissued a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a report on Wednesday, October 2nd.

Get Our Latest Research Report on BIOLASE

BIOLASE Price Performance

Shares of BIOL opened at $0.01 on Monday. The company has a market capitalization of $178,727.45, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The business’s 50 day simple moving average is $0.03 and its 200-day simple moving average is $0.08.

BIOLASE (NASDAQ:BIOLGet Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. The business had revenue of $11.56 million during the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its holdings in BIOLASE, Inc. (NASDAQ:BIOLFree Report) by 1,068.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is owned by institutional investors and hedge funds.

About BIOLASE

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Read More

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.